| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.2 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.2 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.058 | 0.2 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.2 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | StemRegenin 1 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |